AMBA arrives at its May 28 earnings report having already done something remarkable: the stock has gained 40% over the past month to close at $93.57, including a 22% surge in the past week alone. That kind of pre-earnings momentum sharpens every question the print will have to answer.
The most striking feature of the current setup is how little of that rally has attracted short sellers. Short interest runs at roughly 6% of the free float — a meaningful level on paper, but it has barely budged over the past month despite the stock nearly doubling off its April lows. Borrowing costs sit at just 0.46%, firmly in the low-cost category, and availability is exceptionally loose, running at over 6,700% of short interest. That figure means there are far more shares available to lend than are currently borrowed — the lending market shows no trace of squeeze dynamics. The ORTEX short score has drifted slightly lower across recent sessions to 39.8, consistent with fading short-seller conviction rather than escalating pressure.
Options traders are equally relaxed heading into the event. The put/call ratio is at 0.45, almost exactly in line with its 20-day average — a z-score near zero — pointing to neither unusual hedging demand nor aggressive speculative call-buying. The 52-week range for the PCR runs from 0.21 to 0.71, which puts the current reading squarely in the middle of the distribution. Whatever investors feel about tomorrow's print, they are not paying up for protection.
The debate heading into the report splits cleanly. Bulls point to Ambarella's edge AI franchise — computer vision chips for security cameras, automotive systems, and industrial endpoints — where recent design wins with names like Verkada and Zeekr and 37% year-on-year revenue growth suggest the cycle is genuinely inflecting. EPS momentum ranks in the 80th percentile on a 90-day basis, and forward EPS estimates have risen sharply. Rosenblatt maintained its Buy with a $115 target as recently as yesterday, well above current levels. Bears counter that the stock's valuation has stretched sharply on the back of the rally — the P/E is now near 99x and price-to-book has expanded by 1.4 points over the past 30 days — and that concentration risk in a narrow customer base and reliance on leading-edge yields remain genuine execution risks. BofA Securities carries a Neutral rating with a $92 target that the stock has already blown past, raising the bar for what the forward outlook must deliver. That analyst price target consensus of $87.92 now sits below the market price, a rare configuration that frames the print as a referendum on whether current estimates are still too conservative.
The earnings history adds a note of caution. Last February's print sent the stock down 14% on the day and 21% over the following five sessions. That reaction came from a different price level and a different sentiment backdrop, but it illustrates how violently AMBA can move when results disappoint a market priced for momentum.
Tomorrow's report is less about whether edge AI demand is real, and more about whether Ambarella's guidance can justify a stock that has re-rated faster than analyst targets have followed.
See the live data behind this article on ORTEX.
Open AMBA on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
